Partnerships Revance Therapeutics: Clinical Trial Collaboration Agreement (Jan 2025) for a Phase 2a trial of Dermata Compound + Daxxify (daxibotulinumtoxinA); royalty-free cross-licenses, no financial consideration; trial on hold. Reka-Farm: exclusive Spongilla raw-material supply; <1% royalty on net sales of Spongilla-containing products.
Indications
Moderate-to-severe acne(Phase 3)
Status note Phase 3 STAR-1 topline reported Q1 2025; filing calls XYNGARI 'formerly its lead prescription candidate' but states no discontinuation or STAR-1 results in these excerpts. Revance Phase 2a combination trial placed on hold. Company also markets the Tome skincare brand (cosmetic).
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.